Real-world study examines caplacizumab for aTTP: better treatment on the horizon?
NCT ID NCT04985318
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks back at how doctors in Germany prescribed caplacizumab (Cablivi) for acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood clotting disorder. Researchers will analyze data from 350 patients to see how well the drug works outside of clinical trials and to find ways to improve treatment plans. The goal is to develop better guidelines that improve patient outcomes and reduce healthcare costs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- caplacizumab (Cablivi)
- What this could lead to
- If successful, this study could help doctors use caplacizumab more effectively, leading to better outcomes and lower treatment costs for people with aTTP.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients, and the drug's known risks (e.g., bleeding) remain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Cologne
Cologne, 50937, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.